<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Inclusion Body Myositis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Richard</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">University of Texas Southwestern Medical Center</orgName>
								<orgName type="institution" key="instit2">Harry Hines Blvd</orgName>
								<address>
									<postCode>5323, 75235-8897</postCode>
									<settlement>Dallas</settlement>
									<region>TX</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Anthony</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Harvard Medical School</orgName>
								<orgName type="institution" key="instit2">Brigham &amp; Women&apos;s Hospital</orgName>
								<address>
									<postCode>02115</postCode>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Current Science Inc</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Inclusion Body Myositis</title>
					</analytic>
					<monogr>
						<idno type="ISSN">1092-8480</idno>
					</monogr>
					<idno type="MD5">59FD25006DE46C56E2EA2595E0020738</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The three major categories of idiopathic inflammatory myopathy are dermatomyositis, polymyositis, and inclusion body myositis. These inflammatory myopathies are clinically, histologically, and pathogenetically distinct [1••,2,3,4••]. Although sporadic IBM is probably the most common inflammatory myopathy in patients older than 50 years of age, it is frequently misdiagnosed. Accurate diagnosis is important because of the three common idiopathic inflammatory myopathies, IBM is the least likely to improve with immunosuppressive therapy.</p><p>Sporadic IBM presents with an insidious onset of slowly progressive proximal and distal weakness. The slow evolution of the disease process probably accounts in part for the delay in diagnosis, averaging approximately 6 years from the onset of symptoms <ref type="bibr" target="#b6">[5•,</ref><ref type="bibr">Class III]</ref>. Patients with IBM have a unique pattern of weakness, with early weakness and atrophy of the quadriceps, the volar forearm muscles (ie, wrist and finger flexors), and the ankle dorsiflexors. The quadriceps weakness can produce a genu recurvatum or back knee and lead to accelerated degenerative knee arthritis and pain. In addition, muscle involvement in IBM is often asymmetric. As many as 40% of patients complain of dysphagia, which can be so severe that some require cricopharyneal myotomy <ref type="bibr" target="#b7">[6,</ref><ref type="bibr" target="#b8">7]</ref>. Although most patients have no sensory symptoms, evidence of generalized peripheral neuropathy can be detected in up to 30% of patients on clinical examination and electrophysiologic testing <ref type="bibr" target="#b6">[5•,</ref><ref type="bibr">Class III]</ref>.</p><p>The serum creatine kinase level is normal or only mildly elevated. Electromyography demonstrates increased insertional and spontaneous activity with both small and large polyphasic motor unit potentials and early recruitment. Muscle biopsy specimens characteristically demonstrate endomysial inflammation and fibers with one or more rimmed vacuoles. Amyloid deposition is evident on Congo red staining using polarized light or fluorescence techniques <ref type="bibr">[8•]</ref>. Electron microscopy demonstrates 15-to 21-nm cytoplasmic and intranuclear tubulofilaments.</p><p>The pathogenesis of IBM is unknown; it may be a primary inflammatory myopathy like dermatomyositis and polymyositis. The poor clinical response to various immunosuppressive therapies argues against a primary autoimmune basis for IBM <ref type="bibr" target="#b10">[9]</ref>. Askanas et al. <ref type="bibr" target="#b4">[3]</ref> have</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Opinion statement</head><p>Inclusion body myositis (IBM) is usually refractory to immunosuppressive therapy; however, a few reports suggest that a minority of patients with IBM may have a partial, transient response or that therapy may slow progression. Therefore, although we generally discourage the use of immunosuppressive therapy for IBM, if the patient is willing to accept the potential side effects of therapy, a 3-to 6-month trial of oral prednisone can be attempted: 100 mg/d for 2 to 4 weeks, then 100 mg every other day for 2 to 3 months. If prednisone alone produces no improvement after 3 months, oral methotrexate can be added: 10 to 15 mg/wk for 6 to 12 months. If there is no objective clinical improvement in strength after a trial of prednisone alone or prednisone plus methotrexate over the course of 6 to 12 months, we discontinue pharmacologic therapy. Because of the great expense, relative lack of availability, and minimal evidence of benefit of intravenous immunoglobulin (IVIG), we do not recommend this form of immunomodulating therapy for IBM.</p><p>documented the accumulation of "Alzheimer-characteristic proteins" in vacuolated muscle fibers in IBM, supporting the possibility that IBM may be a primary degenerative myopathy.</p><p>Life expectancy does not appear to be significantly altered. Most patients remain ambulatory, although they frequently require or at least benefit from a cane or a wheelchair for walking long distances. Some patients become severely incapacitated, however, and require a wheelchair within 10 to 15 years.</p><p>Unfortunately, patients with IBM do not significantly improve with immunosuppressive treatment. A number of anecdotal reports of small numbers of cases found no sustained benefit with corticosteroid therapy [9-15, Class III]. In our initial study of eight patients [9, Class III], the prednisone dose was 100 mg/d for 4 weeks, followed by 100 mg every other day for at least 6 months. Despite lower serum creatine kinase levels and reduced inflammation demonstrated on posttreatment muscle biopsies, none of the patients improved in strength or function. Interestingly, the number of vacuolated muscle fibers and fibers with amyloid deposition was increased in the follow-up biopsies, suggesting that the accumulation of vacuoles and amyloid may have a role in the pathogenesis of IBM. In our subsequent retrospective study of 11 definite and 7 possible (characteristic phenotype/nondiagnostic biopsy results) patients with IBM, none responded to corticosteroids [5•, Class III].</p><p>A few retrospective unblinded studies have reported mild or transient improvement for an occasional patient with IBM treated with prednisone. Some groups have downplayed the rare patients who appear to experience a transient benefit and point out that all patients ultimately worsen [15, Class III], whereas other researchers emphasize the potential benefit of prednisone therapy <ref type="bibr" target="#b15">[14,</ref><ref type="bibr" target="#b17">16,</ref><ref type="bibr">Class III]</ref>. In two publications, a group of researchers has reported that 40% to 58% of their patients with IBM partially responded to prednisone, although none had a complete remission <ref type="bibr" target="#b17">[16,</ref><ref type="bibr" target="#b18">17,</ref><ref type="bibr">Class III]</ref>. In these two retrospective unblinded studies, however, a positive response could include subjective improvement or lower serum creatine kinase levels following treatment.</p><p>The use of cytotoxic agents for IBM has also generally been disappointing. Nearly all these reports are retrospective and uncontrolled, and patients receiving cytotoxic agents were often included in the results of the corticosteroid trials noted previously [5•,13-16, Class III]. In a retrospective data analysis, Joffe et al. <ref type="bibr" target="#b17">[16,</ref><ref type="bibr">Class III]</ref> reported that 4 of 10 patients (40%) had a partial response to low-dose methotrexate (5 mg/wk) in addition to prednisone. The same group conducted a small (11 patients) unblinded prospective crossover study comparing prednisone plus azathioprine plus oral methotrexate with prednisone plus intravenous methotrexate <ref type="bibr" target="#b18">[17,</ref><ref type="bibr">Class II]</ref>. They found no clinically significant improvement in strength. Serum creatine kinase levels decreased in 66% to 70% of patients, however, and there was no decline in strength over the 6-month treatment period in approximately half the patients in both study arms. They concluded that the combination of immunosuppressive medications stabilized the disease process. The best study to date suggesting that there may be a benefit to treating some patients with immunosuppressive drugs is the retrospective nonrandomized but controlled study done by Sayers et al. <ref type="bibr" target="#b19">[18,</ref><ref type="bibr">Class II]</ref>. In this study, four nontreated patients were compared with 13 patients receiving prednisone alone and 15 patients receiving a combination of prednisone plus another immunosuppressive agent (oral methotrexate, azathioprine, or cyclosporine). All four untreated patients deteriorated. Of the patients treated with prednisone alone, seven (54%) deteriorated, four (31%) stabilized, and two (15%) experienced transient improvement. Of the group receiving prednisone plus another immunosuppressive drug, six (40%) deteriorated, one (6%) stabilized, five (33%) had transient improvement, and three (20%) had long-term improvement. The primary criticism of this report is that deterioration, stabilization, and improvement were all based on nonquantitative global impressions of the patient and physician.</p><p>Regarding other immunosuppressive treatment approaches, Cronin et al. <ref type="bibr" target="#b20">[19,</ref><ref type="bibr">Class III]</ref> reported no response to intravenous cyclophosphamide in two patients. <ref type="bibr">Dau [20,</ref><ref type="bibr"></ref> Class III] reported a partial nonmaintained response to leukocytopheresis in one patient. Jongen et al. <ref type="bibr">[21,</ref> Class III] reported on a case in which oral chlorambucil produced partial improvement followed by stabilization over 15 months. Of four patients with IBM treated with total-body irradiation, three continued to deteriorate; one patient had a subjective transient improvement but then deteriorated [22, Class III].</p><p>There have been three published studies of the use of intravenous immunoglobulin for IBM. The initial uncontrolled study suggested a benefit in three of four patients <ref type="bibr" target="#b24">[23,</ref><ref type="bibr">Class III]</ref>. We were unable to document any significant clinical improvement in nine patients treated with IVIG using induction doses of 2 gm/kg followed by monthly maintenance infusions of 1 gm/kg [24, Class III]. These two unblinded trials led to a prospective double-blind placebo-controlled study [25•, Class I]. Nineteen patients were entered into this study-nine randomized to receive IVIG and 10 receiving placebo. Although the patients who received IVIG had a slightly higher combined manual muscle score compared with the group receiving placebo, this did not reach statistical significance. Two secondary efficacy measurements-quantitative swallowing function measured by ultrasonography and a lower extremity "limb-by-limb" manual muscle score subanalysis-did show statistically significant improvement with IVIG therapy. Nevertheless, this is the only double-blind controlled prospective therapeutic trial for IBM, and it ultimately has to be considered a negative study <ref type="bibr" target="#b27">[26]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment</head><p>• There is no convincing evidence from either noncontrolled or controlled reports that immunosuppressive or immunomodulating therapy produces significant improvement in patients with IBM. A minority of patients may experience a transient improvement in strength or possibly a stabilization or slowing of deterioration. All patients ultimately worsen despite therapy, however. If the patient is informed of the potential risks of immunosuppressive therapy, an empiric trial can be attempted for a defined period of time to determine if the patient is among the minority who may obtain partial benefit. It is acceptable to inform the patient that because IBM usually does not respond to therapy, it is reasonable not to attempt to treat it with these agents. • If an empiric trial is initiated, the first-line therapy is prednisone.</p><p>We recommend that the second-line therapy should be the addition of oral methotrexate to prednisone. Either it may take too long to detect an effect with other chemotherapeutic options (eg, with azathioprine) or there are insufficient data to support an empiric trial (eg, cyclosporine, cyclophosphamide, chlorambucil). Regarding the use of IVIG as an immunomodulating agent, we inform patients that because of the great expense of the drug, its relative shortage, and no clear indication of the drug's effectiveness for IBM, we do not recommend a therapeutic trial of IVIG for this disease.</p><p>If there is no objective benefit to prednisone or prednisone plus methotrexate, we taper the patient off drug therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Corticosteroids</head><p>Standard dosage 100 mg/d in a single morning dose for 2 to 4 weeks. After 2 to 4 weeks, the patient can be immediately switched to 100 mg every other day. Some clinicians prefer to taper the dose to 100 mg every other day over a period of weeks. Continue prednisone at a dose of 100 mg every other day for 2 to 3 months, carefully recording the patient's muscle strength in the arms and legs at monthly visits. At that point, a determination is made whether there has been an objective improvement in strength. If there has been no improvement in strength, the prednisone can be tapered and discontinued quickly over approximately 2 months. Alternatively, a second immunosuppressive drug can be added to the regimen (usually methotrexate), and the prednisone can be tapered at a slower rate, usually 5 mg every 2 weeks. Contraindications There are no absolute contraindications. Relative contraindications include diabetes mellitus, hypertension, glaucoma, history of mania or bipolar disorder, and osteoporosis. Main drug interactions None.</p><p>Main side effects Fluid and weight gain, hypertension, hyperglycemia, hypokalemia, cataracts, glaucoma, gastric irritation, osteoporosis, infection, aseptic femoral necrosis. Special points A chest x-ray and purified protein derivative skin test are obtained before initiating therapy. Calcium supplementation (1 gm/d) and vitamin D are prescribed to prevent osteoporosis. Estrogen supplements are given to postmenopausal woman. Oral bisphosphonates are prescribed for patients with known osteoporosis and for postmenopausal women. There is evidence that oral bisphosphonates are efficacious in preventing osteoporosis in patients taking prednisone <ref type="bibr" target="#b28">[27]</ref>. Bone marrow density is measured annually while patients are taking prednisone. Medication for peptic ulcers or gastritis and hypokalemia is prescribed only if clinically indicated. Fasting blood sugar level, serum potassium level, blood pressure, and weight are checked at each clinic visit, and periodic ophthalmologic evaluations are necessary to check for the development of cataracts and glaucoma. Cost/cost effectiveness Generic prednisone is available and is cost effective (less than $20 monthly). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacologic treatment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cricopharyngeal myotomy</head><p>Standard procedure Cricopharyngeal myotomy. Contraindications None.</p><p>Complications Hemorrhage. This is a relatively simple, low-complication procedure performed by an otolaryngologist. Cost/cost effectiveness The procedure is probably cost effective for patients with severe dysphagia who are aspirating and experiencing progressive weight loss. It is infrequent to have to resort to this surgical procedure in the majority of patients with IBM, however.</p><p>• If IBM is not a primary autoimmune inflammatory myopathy, it is unlikely that immunosuppressive agents will improve strength or function. Slowing the rate of deterioration or stabilizing strength may be the goal. Treating IBM with immunosuppressive drugs may therefore be analogous to treating Duchenne muscular dystrophy with prednisone [28, Class I]. • If the goal in IBM is to slow or prevent disease progression, different trial designs need to be adopted. Given the slow rate of deterioration of most patients, placebo-controlled trials using standard immunosuppressive drugs will most likely need to be 12 or 24 months in length and will require 25 to 30 patients in each arm. Such an effort would necessitate a large multicenter study. The primary efficacy measurement should be quantitative strength assessment by means of maximum voluntary isometric contraction performed by a physical therapist who is unaware of the treatment status of the patient. • Novel drug therapy can be attempted first in smaller open-label studies to determine if the drug can produce significant improvement. For the reasons cited previously, this type of dramatic improvement is unlikely to occur. Currently, there is a small open-label multicenter pilot study underway using beta-interferon for IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Surgery</head><p>Emerging therapies</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc>MethotrexateStandard dosage Oral methotrexate is administered one day a week. Begin at a total dose of 7.5 mg and increase by one 2.5-mg tablet weekly to a dose of 15 mg/wk. Methotrexate can be given as a single dose, or, if there is gastrointestinal discomfort, it can be given in three divided doses 12 hours apart. If doses of more than 20 mg/wk are desired, parenteral (intravenous or intramuscular) administration is used. Methotrexate is available in a generic form. The average monthly cost is $90 to $100.• A few patients with severe dysphagia due to cricopharyngeus muscle dysfunction have benefited from cricopharyngeus muscle myotomy [6,7, Class III].</figDesc><table><row><cell>Contraindications There are no absolute contraindications. Relative contraindications include</cell></row><row><cell>underlying pulmonary or hepatic disease.</cell></row><row><cell>Main drug interactions None.</cell></row><row><cell>Main side effects Pulmonary fibrosis, hepatotoxicity, infection, infertility, leukopenia, infection,</cell></row><row><cell>alopecia, gastric irritation, stomatitis, teratogenicity, neoplasia.</cell></row><row><cell>Special points Monthly liver enzyme testing (including gamma-glutamyltransferase) and blood</cell></row><row><cell>count must be done.</cell></row><row><cell>Cost/cost effectiveness</cell></row></table></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Recommended Reading Papers of particular interest, published recently, have been highlighted as: • Of special interest •• Of outstanding interest</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">••</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Clin</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="615" to="648" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">A good review of the three most frequent forms of idiopathic inflammatory myopathy: dermatomyositis, polymyositis, and inclusion body myositis</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Inclusion body myositis, a review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1105" to="1114" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<title level="m">Inclusion-Body Myositis and Myopathies</title>
				<meeting><address><addrLine>Cambridge, UK</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Diagnostic criteria for sporadic inclusion body myositis were proposed</title>
		<author>
			<persName><forename type="first">••</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dimauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="705" to="713" />
			<date type="published" when="1995">1995. 1995</date>
		</imprint>
	</monogr>
	<note>Summary of the international workshop on inclusion body myositis</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The authors point out that patients with &quot;steroid-resistant polymyositis&quot; frequently have the typical pattern of weakness seen in inclusion body myositis (IBM), even if the classic morphologic findings are not seen in the initial muscle biopsy specimen. The authors labeled the disorder in this group as</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Gronseth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="581" to="586" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>Inclusion body myositis: clinical and pathological boundaries. possible&quot; or &quot;probable&quot; IBM. Often, a second or third muscle biopsy is needed to confirm the diagnosis</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Management of dysphagia in inclusion body myositis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Darrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="313" to="317" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Adensina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="470" to="473" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The initial report describing amyloid deposition in the muscle of patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gales</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1229" to="1234" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: explanation for poor response to therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahenk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1302" to="1304" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Inclusionbody myositis: a distinct variety of idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Eisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="8" to="17" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Inclusionbody myositis. A corticosteroid-resistant idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Danon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Reyes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">H</forename><surname>Perurena</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="760" to="764" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Spectrum of inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Ringel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Kenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Neville</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1154" to="1157" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis presenting as treatment-resistant polymyositis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Calabrese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mitsumoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Chou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="397" to="403" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Clinical heterogeneity and treatment response in inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Sulaiman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Garancis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Wortmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="734" to="740" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Björdander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurol Scand</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="123" to="131" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Drug therapy of idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Joffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="379" to="387" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hicks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="225" to="235" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis: analysis of 32 cases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Sayers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Calabrese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1385" to="1389" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cronin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1225" to="1228" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Leukocytapheresis in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Dau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Apheresis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="167" to="170" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Inclusionbody myositis responding to long-term chlorambucil treatment</title>
		<author>
			<persName><forename type="first">Pjh</forename><surname>Jongen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Terlaak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lba</forename><surname>Vandeputte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="576" to="578" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Total-body irradiation not effective in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kelly</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">Madoc-</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Adelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1264" to="1266" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Treatment of inclusionbody myositis with high-dose intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Soueidan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="876" to="879" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: treatment with intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1516" to="1518" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Although there was a trend toward improvement in some patients, this study is widely interpreted as showing no significant benefit of intravenous immunoglobulin in IBM</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sonies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dambrosia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="712" to="716" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>The only placebo-controlled therapeutic trial ever performed on patients with inclusion body myositis (IBM)</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The therapeutic dilemma of inclusion body myositis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="567" to="568" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Alendronate for prevention and treatment of glucocorticoid induced osteoporosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Saag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Emkey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Schnitzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="292" to="299" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Randomized, double-blind six-month trial of prednisone in Duchenne muscular dystrophy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Moxley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="1592" to="1597" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
